Lifetime Cancer Risks in Individuals with Germline PTEN Mutations
暂无分享,去创建一个
C. Eng | M. Tan | L. Rybicki | J. Mester | M. Orloff | J. Ngeow | Mohammed S Orloff
[1] C. Eng,et al. Analysis of prevalence and degree of macrocephaly in patients with germline PTEN mutations and of brain weight in Pten knock-in murine model , 2011, European Journal of Human Genetics.
[2] Charis Eng,et al. A clinical scoring system for selection of patients for PTEN mutation testing is proposed on the basis of a prospective study of 3042 probands. , 2011, American journal of human genetics.
[3] W. Foulkes,et al. Family history of cancer and cancer risks in women with BRCA1 or BRCA2 mutations. , 2010, Journal of the National Cancer Institute.
[4] C. Eng,et al. Frequent gastrointestinal polyps and colorectal adenocarcinomas in a prospective series of PTEN mutation carriers. , 2010, Gastroenterology.
[5] Rosalind Eeles,et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. , 2010, JAMA.
[6] L. Chin,et al. Cooperative interactions of PTEN deficiency and RAS activation in melanoma metastasis , 2010, Oncogene.
[7] Z. Latiff,et al. Bannayan Riley Ruvalcaba syndrome. , 2010, Annals of the Academy of Medicine, Singapore.
[8] Kandamurugu Manickam,et al. Confirmation study of PTEN mutations among individuals with autism or developmental delays/mental retardation and macrocephaly , 2010, Autism research : official journal of the International Society for Autism Research.
[9] Pier Paolo Pandolfi,et al. Subtle variations in Pten dose determine cancer susceptibility , 2010, Nature Genetics.
[10] C. Eng,et al. PTEN hamartoma tumor syndrome: An overview , 2009, Genetics in Medicine.
[11] E. Bakker,et al. Diagnostic guidelines for high‐resolution melting curve (HRM) analysis: An interlaboratory validation of BRCA1 mutation scanning using the 96‐well LightScanner™ , 2009, Human mutation.
[12] R. DePinho,et al. BRafV600E cooperates with Pten silencing to elicit metastatic melanoma , 2009, Nature Genetics.
[13] C. Eng,et al. Cowden syndrome-affected patients with PTEN promoter mutations demonstrate abnormal protein translation. , 2007, American journal of human genetics.
[14] C Eng,et al. Subset of individuals with autism spectrum disorders and extreme macrocephaly associated with germline PTEN tumour suppressor gene mutations , 2005, Journal of Medical Genetics.
[15] C Eng,et al. Will the real Cowden syndrome please stand up (again)? Expanding mutational and clinical spectra of the PTEN hamartoma tumour syndrome , 2004, Journal of Medical Genetics.
[16] Stella M. Yu. Healthy People 2010 , 1998, Maternal and Child Health Journal.
[17] Min Cheol Lee,et al. Expression of PTEN in renal cell carcinoma and its relation to tumor behavior and growth , 2003, Journal of surgical oncology.
[18] P. Pandolfi,et al. Pten Dose Dictates Cancer Progression in the Prostate , 2003, PLoS biology.
[19] D. Zwijnenburg,et al. Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. , 2002, Nucleic acids research.
[20] H. Lehr,et al. Loss of tumor suppressor protein PTEN during renal carcinogenesis , 2002, International journal of cancer.
[21] B. Delahunt,et al. Intragenic PTEN/MMAC1 Loss of Heterozygosity in Conventional (Clear-Cell) Renal Cell Carcinoma is Associated with Poor Patient Prognosis , 2002, Modern Pathology.
[22] Klein Rj,et al. Age adjustment using the 2000 projected U.S. population. , 2001 .
[23] C. Schoenborn,et al. Age adjustment using the 2000 projected U.S. population. , 2001, Healthy People 2010 statistical notes : from the Centers for Disease Control and Prevention/National Center for Health Statistics.
[24] C. Eng. Will the real Cowden syndrome please stand up: revised diagnostic criteria , 2000, Journal of medical genetics.
[25] M. Wigler,et al. The lipid phosphatase activity of PTEN is critical for its tumor supressor function. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[26] C Eng,et al. Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation. , 1998, Human molecular genetics.
[27] Hong Sun,et al. TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta. , 1997, Cancer research.
[28] Ross Ihaka,et al. Gentleman R: R: A language for data analysis and graphics , 1996 .
[29] E. Mariman,et al. Localization of the gene for Cowden disease to chromosome 10q22–23 , 1996, Nature Genetics.
[30] J. Doyle,et al. Cowden's Disease with Associated Malignant Melanoma , 1984, International journal of dermatology.